The latest price target for Lyell Immunopharma (NASDAQ:LYEL) was reported by HC Wainwright & Co. on December 9, 2025. The analyst firm set a price target for $45.00 expecting LYEL to rise to within 12 months (a possible 36.80% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Lyell Immunopharma (NASDAQ:LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma upgraded their buy rating.

The last upgrade for Lyell Immunopharma Inc happened on December 9, 2025 when HC Wainwright & Co. raised their price target to $45. HC Wainwright & Co. previously had a neutral for Lyell Immunopharma Inc.

The last downgrade for Lyell Immunopharma Inc happened on October 30, 2024 when B of A Securities changed their price target from $6 to $1 for Lyell Immunopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.

While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a upgraded with a price target of $20.00 to $45.00. The current price Lyell Immunopharma (LYEL) is trading at is $32.90, which is within the analyst’s predicted range.